H. Lundbeck B Shares Plunge 5.3% After Deutsche Bank Downgrade to Sell

H. Lundbeck B shares fell 5.3% to trade at DKK 42.28 on Tuesday after Deutsche Bank issued a sharp downgrade from Hold to Sell and cut its price target to DKK 36 from DKK 40, implying roughly 15% further downside. The move, reported by TipRanks and StreetInsider, centers on growing risks to Rexulti, which accounts for about 25% of group revenue, plus near-term dilution pressure from an ongoing A-to-B share exchange offer.

Deutsche Bank Downgrades to Sell on Rexulti Risks: 6x FY27 P/E, 25% Revenue Exposure and Share Dilution

Deutsche Bank analyst Niall Alexander lowered the rating to Sell and the target to DKK 36, valuing the stock on a fiscal-year 2027 price-to-earnings multiple of approximately 6x — a steep discount of around 66% to the average among European pharmaceutical small- and mid-cap peers, according to the bank’s note cited by market reports.

The core of the thesis is pressure on Rexulti (brexpiprazole). The product generated DKK 6.205 billion in revenue in full-year 2025 (up 23% at constant exchange rates and representing 25% of total sales), driven by strong U.S. demand in major depressive disorder and agitation associated with Alzheimer’s dementia (AADAD). AADAD prescriptions have risen sharply, contributing more than 24% of U.S. Rexulti volume.

Analysts flagged intensifying competition from Axsome’s Auvelity, which received an expanded FDA approval for Alzheimer’s agitation and is positioned as a non-antipsychotic alternative without the black-box warning that applies to Rexulti. In addition, Rexulti has been selected for Inflation Reduction Act (IRA) price negotiation, with the negotiated lower price scheduled to take effect in 2028. Patent protection also faces a significant cliff around 2029.

Separately, Lundbeckfond Invest A/S — the investment arm of the controlling Lundbeck Foundation — is running a voluntary exchange offer that allows holders of A-shares to convert into B-shares on a 1:1 basis. The offer period runs through 16:00 CEST on 16 September 2026. The B-share class is significantly more liquid (approximately seven times more liquid than the A-share since the dual-class structure was introduced in 2022) and has historically traded at a premium; the exchange is expected to increase the free float of B-shares and create near-term dilution dynamics.

At the time of writing, the stock was trading well below its 52-week high of DKK 47.78 but remained above the 52-week low of DKK 35.30. Average analyst 12-month target stood near DKK 48–49 before the latest cut.

Sell Rating and 25% Revenue Risk Trigger Sharp Selling Pressure

The combination of a high-profile Sell rating with an explicit 6x 2027 P/E framework and concrete threats to a 25% revenue pillar triggered immediate selling. Investors reassessed the durability of Rexulti’s growth trajectory in the face of Auvelity’s market entry and the upcoming IRA price reduction, while the exchange offer added a technical overhang of potential B-share supply. Broader risk-off conditions in U.S. equity markets and cautious trading on the OMX Copenhagen 25 amplified the move, leaving limited room for buyers to step in on the day.

DKK 24.6bn Revenue, Dual-Class Shares and Rexulti’s IRA Overhang

H. Lundbeck A/S is a Danish specialty pharmaceutical company focused on brain diseases. Strategic brands — Rexulti, Vyepti (migraine), the Abilify LAI franchise and Brintellix/Trintellix — accounted for the large majority of 2025 revenue of approximately DKK 24.6 billion. Rexulti’s U.S. success, particularly in the AADAD indication approved in 2023, has been a key growth driver, with total prescriptions rising more than 24% year-on-year in recent periods.

The dual-class share structure (A-shares carrying 10 votes each, B-shares 1 vote) was introduced in 2022. Lundbeckfond Invest, controlled by the Lundbeck Foundation, remains the dominant shareholder. The current exchange offer is designed to give minority A-shareholders access to the more liquid B-share class without cash consideration.

Rexulti’s selection for IRA negotiation was expected given its Medicare spending profile (more than USD 1 billion in recent 12-month data). The 2028 price cut and the later patent cliff remain the two largest medium-term overhangs identified by multiple brokers.

Exchange Offer Closes 16 Sept, Focus Turns to Rexulti vs Auvelity and 2029 Patent Cliff

The exchange offer closes on 16 September 2026; preliminary results are expected the following day, with settlement targeted around 21 September. Investors will watch the final volume of A-shares tendered for any lasting impact on B-share free float and liquidity.

Attention will also turn to subsequent quarterly updates on Rexulti prescription trends versus Auvelity, any further commentary on IRA negotiations, and pipeline progress that could offset the 2029 patent cliff. Consensus still shows a Buy-leaning rating overall, with average targets above the current price, but Deutsche Bank’s more conservative stance has shifted the near-term narrative toward caution.